Article thumbnail
Location of Repository

Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC

By Zhong-Zhe Lin, Yung-Ming Jeng, Fu-Chang Hu, Hung-Wei Pan, Hsin-Wei Tsao, Po-Lin Lai, Po-Huang Lee, Ann-Lii Cheng and Hey-Chi Hsu
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2940801
Provided by: PubMed Central

Suggested articles

Citations

  1. (2009). AL: Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival. Cancer Epidemiol Biomarkers Prev
  2. (2009). AL: The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.
  3. (2008). Aurora kinases as targets for cancer therapy. Cancer Treat Rev
  4. (2005). Aurora-A - a guardian of poles. Nat Rev Cancer
  5. (2004). Brautigan DL: Activation of AuroraA kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein. Proc Natl Acad Sci USA
  6. (2002). Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology
  7. (2008). DR: Aurora Kinases as Anticancer Drug Targets. Clin Cancer Res
  8. (1996). DS: Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery
  9. (1988). DS: Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. Cancer
  10. (2007). Earnshaw WC: Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol
  11. (2001). Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology
  12. (2002). Global cancer statistics
  13. (2006). Greenberg NM: Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res
  14. (2002). HC: Downregulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation.
  15. (2004). HC: High alphafetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
  16. (2004). HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res
  17. (2002). Hepatocellular carcinoma: an epidemiologic view.
  18. (2007). Hsu HC: Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res
  19. (2003). Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer
  20. (2007). KL: Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology
  21. (2000). Lemeshow S: Applied logistic regression.
  22. (1999). Lemeshow S: Applied survival analysis: regression modeling of time to event data.
  23. (2008). Novel advancements in the management of hepatocellular carcinoma in
  24. (1993). P: S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eukaryotic cells and tissues. Nucleic Acids Res
  25. (1991). Peng SY: Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology
  26. (1993). Peng SY: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res
  27. (2000). Peng SY: ß-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.
  28. (1994). PH: Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC.
  29. (2005). Portella G: Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation.
  30. (2007). Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res
  31. (2007). S: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res
  32. (1998). S: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet
  33. (2004). Schlegelberger B: Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc Natl Acad Sci USA
  34. (2003). SH: Genomic imbalances in Korean hepatocellular carcinoma. Cancer Genet Cytogenet
  35. (2006). SS: Validating Aurora B as an anti-cancer drug target.
  36. (2008). Tanaka H: Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy.
  37. (2004). Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer
  38. (2002). Yang YW: Cancer epidemiology and control in Taiwan: a brief review. Jpn JClin Oncol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.